List of Tables
Table 1. Global Female Sexual Dysfunction Treatment Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Female Sexual Dysfunction Treatment Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Female Sexual Dysfunction Treatment Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Female Sexual Dysfunction Treatment Drug Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Female Sexual Dysfunction Treatment Drug Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Female Sexual Dysfunction Treatment Drug Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Female Sexual Dysfunction Treatment Drug Sales by Region (2020-2025) & (K Units)
Table 8. Global Female Sexual Dysfunction Treatment Drug Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Female Sexual Dysfunction Treatment Drug Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Female Sexual Dysfunction Treatment Drug Sales Share by Manufacturers (2020-2025)
Table 12. Global Female Sexual Dysfunction Treatment Drug Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Female Sexual Dysfunction Treatment Drug Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Female Sexual Dysfunction Treatment Drug by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Female Sexual Dysfunction Treatment Drug as of 2024)
Table 16. Global Female Sexual Dysfunction Treatment Drug Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Female Sexual Dysfunction Treatment Drug Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Female Sexual Dysfunction Treatment Drug Manufacturing Base and Headquarters
Table 19. Global Female Sexual Dysfunction Treatment Drug Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Female Sexual Dysfunction Treatment Drug Sales by Type (2020-2025) & (K Units)
Table 23. Global Female Sexual Dysfunction Treatment Drug Sales by Type (2026-2031) & (K Units)
Table 24. Global Female Sexual Dysfunction Treatment Drug Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Female Sexual Dysfunction Treatment Drug Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Female Sexual Dysfunction Treatment Drug ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Female Sexual Dysfunction Treatment Drug Sales by Application (2020-2025) & (K Units)
Table 29. Global Female Sexual Dysfunction Treatment Drug Sales by Application (2026-2031) & (K Units)
Table 30. Female Sexual Dysfunction Treatment Drug High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Female Sexual Dysfunction Treatment Drug Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Female Sexual Dysfunction Treatment Drug Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Female Sexual Dysfunction Treatment Drug ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Female Sexual Dysfunction Treatment Drug Growth Accelerators and Market Barriers
Table 37. North America Female Sexual Dysfunction Treatment Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Female Sexual Dysfunction Treatment Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Female Sexual Dysfunction Treatment Drug Growth Accelerators and Market Barriers
Table 40. Europe Female Sexual Dysfunction Treatment Drug Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Female Sexual Dysfunction Treatment Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Female Sexual Dysfunction Treatment Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Female Sexual Dysfunction Treatment Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Female Sexual Dysfunction Treatment Drug Growth Accelerators and Market Barriers
Table 45. Southeast Asia Female Sexual Dysfunction Treatment Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Female Sexual Dysfunction Treatment Drug Investment Opportunities and Key Challenges
Table 47. Central and South America Female Sexual Dysfunction Treatment Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Female Sexual Dysfunction Treatment Drug Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Female Sexual Dysfunction Treatment Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Pfizer Corporation Information
Table 51. Pfizer Description and Major Businesses
Table 52. Pfizer Product Models, Descriptions and Specifications
Table 53. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Pfizer Sales Value Proportion by Product in 2024
Table 55. Pfizer Sales Value Proportion by Application in 2024
Table 56. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 57. Pfizer Female Sexual Dysfunction Treatment Drug SWOT Analysis
Table 58. Pfizer Recent Developments
Table 59. Teva Pharmaceuticals Corporation Information
Table 60. Teva Pharmaceuticals Description and Major Businesses
Table 61. Teva Pharmaceuticals Product Models, Descriptions and Specifications
Table 62. Teva Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Teva Pharmaceuticals Sales Value Proportion by Product in 2024
Table 64. Teva Pharmaceuticals Sales Value Proportion by Application in 2024
Table 65. Teva Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 66. Teva Pharmaceuticals Female Sexual Dysfunction Treatment Drug SWOT Analysis
Table 67. Teva Pharmaceuticals Recent Developments
Table 68. Duchesnay Corporation Information
Table 69. Duchesnay Description and Major Businesses
Table 70. Duchesnay Product Models, Descriptions and Specifications
Table 71. Duchesnay Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Duchesnay Sales Value Proportion by Product in 2024
Table 73. Duchesnay Sales Value Proportion by Application in 2024
Table 74. Duchesnay Sales Value Proportion by Geographic Area in 2024
Table 75. Duchesnay Female Sexual Dysfunction Treatment Drug SWOT Analysis
Table 76. Duchesnay Recent Developments
Table 77. Sprout Pharmaceuticals Corporation Information
Table 78. Sprout Pharmaceuticals Description and Major Businesses
Table 79. Sprout Pharmaceuticals Product Models, Descriptions and Specifications
Table 80. Sprout Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Sprout Pharmaceuticals Sales Value Proportion by Product in 2024
Table 82. Sprout Pharmaceuticals Sales Value Proportion by Application in 2024
Table 83. Sprout Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 84. Sprout Pharmaceuticals Female Sexual Dysfunction Treatment Drug SWOT Analysis
Table 85. Sprout Pharmaceuticals Recent Developments
Table 86. Cosette Pharmaceuticals Corporation Information
Table 87. Cosette Pharmaceuticals Description and Major Businesses
Table 88. Cosette Pharmaceuticals Product Models, Descriptions and Specifications
Table 89. Cosette Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Cosette Pharmaceuticals Sales Value Proportion by Product in 2024
Table 91. Cosette Pharmaceuticals Sales Value Proportion by Application in 2024
Table 92. Cosette Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
Table 93. Cosette Pharmaceuticals Female Sexual Dysfunction Treatment Drug SWOT Analysis
Table 94. Cosette Pharmaceuticals Recent Developments
Table 95. Lupin Corporation Information
Table 96. Lupin Description and Major Businesses
Table 97. Lupin Product Models, Descriptions and Specifications
Table 98. Lupin Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Lupin Recent Developments
Table 100. Key Raw Materials Distribution
Table 101. Raw Materials Key Suppliers
Table 102. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 103. Milestones in Production Technology Evolution
Table 104. Distributors List
Table 105. Market Trends and Market Evolution
Table 106. Market Drivers and Opportunities
Table 107. Market Challenges, Risks, and Restraints
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Female Sexual Dysfunction Treatment Drug Product Picture
Figure 2. Global Female Sexual Dysfunction Treatment Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Estrogen Therapy Product Picture
Figure 4. Ospemifene Product Picture
Figure 5. Flibanserin Product Picture
Figure 6. Bremelanotide Product Picture
Figure 7. Others Product Picture
Figure 8. Global Female Sexual Dysfunction Treatment Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Hospital Pharmacies
Figure 10. Private Clinics
Figure 11. Retail Pharmacies
Figure 12. E-Commerce (B2B)
Figure 13. E-Commerce (B2C)
Figure 14. Female Sexual Dysfunction Treatment Drug Report Years Considered
Figure 15. Global Female Sexual Dysfunction Treatment Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 17. Global Female Sexual Dysfunction Treatment Drug Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 18. Global Female Sexual Dysfunction Treatment Drug Revenue Market Share by Region (2020-2031)
Figure 19. Global Female Sexual Dysfunction Treatment Drug Sales (2020-2031) & (K Units)
Figure 20. Global Female Sexual Dysfunction Treatment Drug Sales (CAGR) by Region (2020-2031) (K Units)
Figure 21. Global Female Sexual Dysfunction Treatment Drug Sales Market Share by Region (2020-2031)
Figure 22. Top 5 and Top 10 Manufacturers Female Sexual Dysfunction Treatment Drug Sales Volume Market Share in 2024
Figure 23. Global Female Sexual Dysfunction Treatment Drug Revenue Market Share Ranking (2024)
Figure 24. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 25. Estrogen Therapy Revenue Market Share by Manufacturer in 2024
Figure 26. Ospemifene Revenue Market Share by Manufacturer in 2024
Figure 27. Flibanserin Revenue Market Share by Manufacturer in 2024
Figure 28. Bremelanotide Revenue Market Share by Manufacturer in 2024
Figure 29. Others Revenue Market Share by Manufacturer in 2024
Figure 30. Global Female Sexual Dysfunction Treatment Drug Sales Market Share by Type (2020-2031)
Figure 31. Global Female Sexual Dysfunction Treatment Drug Revenue Market Share by Type (2020-2031)
Figure 32. Global Female Sexual Dysfunction Treatment Drug Sales Market Share by Application (2020-2031)
Figure 33. Global Female Sexual Dysfunction Treatment Drug Revenue Market Share by Application (2020-2031)
Figure 34. North America Female Sexual Dysfunction Treatment Drug Sales YoY (2020-2031) & (K Units)
Figure 35. North America Female Sexual Dysfunction Treatment Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) in 2024
Figure 37. North America Female Sexual Dysfunction Treatment Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Female Sexual Dysfunction Treatment Drug Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Female Sexual Dysfunction Treatment Drug Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Female Sexual Dysfunction Treatment Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) in 2024
Figure 47. Europe Female Sexual Dysfunction Treatment Drug Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Female Sexual Dysfunction Treatment Drug Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 52. France Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Female Sexual Dysfunction Treatment Drug Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Female Sexual Dysfunction Treatment Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Female Sexual Dysfunction Treatment Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Female Sexual Dysfunction Treatment Drug Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 67. India Female Sexual Dysfunction Treatment Drug Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Female Sexual Dysfunction Treatment Drug Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Female Sexual Dysfunction Treatment Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Female Sexual Dysfunction Treatment Drug Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Female Sexual Dysfunction Treatment Drug Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Female Sexual Dysfunction Treatment Drug Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Female Sexual Dysfunction Treatment Drug Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Female Sexual Dysfunction Treatment Drug Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Female Sexual Dysfunction Treatment Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Female Sexual Dysfunction Treatment Drug Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Female Sexual Dysfunction Treatment Drug Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Female Sexual Dysfunction Treatment Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Female Sexual Dysfunction Treatment Drug Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Female Sexual Dysfunction Treatment Drug Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Female Sexual Dysfunction Treatment Drug Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Female Sexual Dysfunction Treatment Drug Revenue (2020-2025) & (US$ Million)
Figure 88. Female Sexual Dysfunction Treatment Drug Industry Chain Mapping
Figure 89. Regional Female Sexual Dysfunction Treatment Drug Manufacturing Base Distribution (%)
Figure 90. Global Female Sexual Dysfunction Treatment Drug Production Market Share by Region (2020-2031)
Figure 91. Female Sexual Dysfunction Treatment Drug Production Process
Figure 92. Regional Female Sexual Dysfunction Treatment Drug Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
